Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 19, 2007

Cancer Therapeutics and an Australian Medical Institute Join Forces to Develop Anticancer Drugs against Unique Target

  • Cancer Therapeutics CRC and the Queensland Institute of Medical Research (QIMR) agreed to work together to discover and develop new treatments for cancer. The R&D work will focus on a particular protein target that is reportedly critical to the genetic repair processes that promote cancer cell survival and keep them replicating.

    Kum Kum Khanna, Ph.D., and Derek Richard in the Cancer and Cell Biology Division at QIMR identified this molecule. The biology of the protein appears to make it an extremely valuable target for therapeutic intervention, according to Dr. Khanna.

    By discovering small molecules that inhibit the protein, Cancer Therapeutics CRC hopes to develop drugs that may stop cancers from growing and promote cancer cell death.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »